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Purpose of the study
A wide range of hepatotoxicity rates associated with
antiretroviral drugs (ARV) has been reported in different
studies. Reasons for this include diverse populations,
with different prevalence of viral hepatitis coinfection,
exposure to diverse ARV and variable criteria to define
liver toxicity across studies. The liver safety of regimens
including efavirenz (EFV), nevirapine (NVP) or boosted-
protease inhibitors (PI/r) has not been compared in a
single large cohort of HIV/HCV-coinfected patients
with a uniform definition of hepatotoxicity. Because of
this, we evaluated the incidence and risk factors for
grade 3 or 4 ALT or AST elevations (TE) and grade 4
total bilirubin elevations (TBE) among ARV-naïve HIV/
HCV-coinfected patients with an initial regimen includ-
ing two nucleoside analogs (NRTIs) plus EFV, NVP or a
PI/r.
Methods
Retrospective multicenter cohort (January 2000-June
2006) of 745 HIV/HCV-coinfected patients starting their
first ARV treatment consisting of two NRTIs plus either
EFV, NVP or PI/r. Patients were included if they were
exposed to ARV for one week or more and had evalua-
tions within the first three months of follow-up. Defini-
tion of grade 3 or 4 TE: 1) Normal baseline ALT or
AST levels: ALT or AST elevations ≥5 times above the
upper limit of normal (ULN); 2) Baseline ALT or AST
levels above the ULN: ALT or AST elevations ≥3.5
times the baseline values Definition of grade 4 TBE:
Increases of total bilirubin ≥5 mg/dl.
Summary of results
323 (43%) patients received EFV, 126 (17%) NVP and
296 (40%) PI/r. Grade 3 or 4 TE were observed in 19
(5.9%) individuals on EFV, 14 (11%) on NVP and 31
(10.5%) on PI/r (global comparison, p=0.068; EFV vs.
NVP, p=0.056; EFV vs. PI/r, p=0.036; NVP vs. PI/r,
p=0.38). Grade 4 TBE were identified in 7 (2.2%)
patients on EFV, 1 (0.8%) on NVP and 11 (3.7%) on PI/r
(p=0.19). Severe TBE was detected in 5 (12%) and 15
(2%) patients with and without cirrhosis, respectively
(p=0.003). Discontinuations due to hepatotoxicity were:
13 (4%) patients on EFV, 16 (13%) on NVP and 17 (6%)
on PI/r (global comparison, p=0.003; EFV vs. NVP,
p=0.001; EFV vs. PI/r, p=0.320; NVP vs. PI/r, p=0.015).
Conclusions
Liver tolerability of regimens including EFV, NVP or PI/r
is generally good in ARV-naïve HIV/HCV-coinfected
patients. Severe TE are less commonly seen with EFV
than with NVP or PI/r. Discontinuations due to hepato-
toxicity were less frequent for patients receiving EFV
than for those treated with NVP.
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